5-bromo-2-(2-chloro-6-fluoro-phenyl)-1H-pyrrolo[2,3-b]pyridine | 1443684-80-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 5-bromo-2-(2-chloro-6-fluoro-phenyl)-1H-pyrrolo[2,3-b]pyridine
• 英文别名: 5-bromo-2-(2-chloro-6-fluorophenyl)-1H-pyrrolo[2,3-b]pyridine
• CAS: 1443684-80-7
• 化学式: C₁₃H₇BrClFN₂
• 分子量: 325.567
• InChiKey: XRYKMABMEWJCKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-bromo-2-(2-chloro-6-fluoro-phenyl)-1H-pyrrolo[2,3-b]pyridine 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 6.0h， 生成 2-(2-chloro-6-fluoro-phenyl)-5-(2-ethyl-5-pyrazin-2-yl-2H-pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridine
  参考文献：
  名称：

  7-AZAINDOLE INHIBITORS OF CRAC

  摘要：

  公开了公式(I)的化合物： 用于治疗与IL-2抑制有关的自身免疫和炎症性疾病，通过调节钙释放激活钙(CRAC)通道。还公开了制造和使用这些化合物用于治疗与CRAC通道相关的疾病的方法。

  公开号：

  US20130158049A1
• 作为产物：
  描述：

  5-bromo-3-[(2-chloro-6-fluorophenyl)ethynyl]pyridin-2-amine 在 potassium tert-butylate 作用下， 以 N-甲基吡咯烷酮 为溶剂， 以34%的产率得到5-bromo-2-(2-chloro-6-fluoro-phenyl)-1H-pyrrolo[2,3-b]pyridine
  参考文献：
  名称：

  Discovery of 7-azaindole derivatives as potent Orai inhibitors showing efficacy in a preclinical model of asthma

  摘要：

  Synthesis and SAR of a series of 7-azaindoles as Orai channel inhibitors showing good potency inhibiting IL-2 production in Jurkat cells is described. Compound 14d displaying best pharmacokinetic properties was further characterized in a model of allergen induced asthma showing inhibition in the number of eosinophils in BALF. High lipophilicity remains as one of the main challenges for this class of compounds. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.01.063

文献信息

• New bicyclic compounds as crac channel modulators
  申请人：Almirall, S.A.

  公开号：EP2738172A1

  公开（公告）日：2014-06-04

  The present invention relates to novel compounds which are inhibitors of CRAC channel activity. This invention also relates to pharmaceutical compositions containing them, process for their preparation and their use in therapy.

  这项发明涉及一种新型化合物，它们是CRAC通道活性的抑制剂。该发明还涉及含有这些化合物的药物组合物，它们的制备方法以及它们在治疗中的应用。
• [EN] 7-AZAINDOLE INHIBITORS OF CRAC<br/>[FR] INHIBITEURS 7-AZAINDOLE DU CRAC
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013092467A1

  公开（公告）日：2013-06-27

  Disclosed are compounds of Formula (I), useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of making and using the compounds for treatment of diseases associated with CRAC channels.
• 7-AZAINDOLE INHIBITORS OF CRAC
  申请人：Hoffmann-La Roche Inc.

  公开号：US20130158049A1

  公开（公告）日：2013-06-20

  Disclosed are compounds of Formula (I): useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of making and using the compounds for treatment of diseases associated with CRAC channels.

  公开了公式(I)的化合物： 用于治疗与IL-2抑制有关的自身免疫和炎症性疾病，通过调节钙释放激活钙(CRAC)通道。还公开了制造和使用这些化合物用于治疗与CRAC通道相关的疾病的方法。
• Discovery of 7-azaindole derivatives as potent Orai inhibitors showing efficacy in a preclinical model of asthma
  作者：Cristina Esteve、Jacob González、Sílvia Gual、Laura Vidal、Soledad Alzina、Sonia Sentellas、Irene Jover、Raquel Horrillo、Jorge De Alba、Montserrat Miralpeix、Gema Tarrasón、Bernat Vidal

  DOI：10.1016/j.bmcl.2015.01.063

  日期：2015.3

  Synthesis and SAR of a series of 7-azaindoles as Orai channel inhibitors showing good potency inhibiting IL-2 production in Jurkat cells is described. Compound 14d displaying best pharmacokinetic properties was further characterized in a model of allergen induced asthma showing inhibition in the number of eosinophils in BALF. High lipophilicity remains as one of the main challenges for this class of compounds. (C) 2015 Elsevier Ltd. All rights reserved.